公开(公告)号：EP1432431A2

公开(公告)日：2004-06-30

申请号：EP02766319.4

申请日：2002-10-04

申请人： Genetics Institute, LLC

发明人： CARTER, Laura ,  WHITTERS, Matthew, J. ,  COLLINS, Mary ,  YOUNG, Deborah, A. ,  LARSEN, Glenn ,  DONALDSON, Debra, D. ,  LOWE, Leslie, D. ,  DUNUSSI, Kyri ,  MA, Margery ,  WITEK, JoAnn, S. ,  KASAIAN, Marion, T. ,  UNGAR, Michelle ,  CARRENO, Beatriz

IPC分类号： A61K38/00

CPC分类号： A61K31/519 ,  A61K31/42 ,  A61K31/453 ,  A61K38/1793 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2086 ,  A61K45/06 ,  C07K2319/30 ,  A61K2300/00

摘要： Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

公开(公告)号：EP1432431B1

公开(公告)日：2017-05-10

申请号：EP02766319.4

申请日：2002-10-04

申请人： Genetics Institute LLC

发明人： CARTER, Laura ,  WHITTERS, Matthew, J. ,  COLLINS, Mary ,  YOUNG, Deborah, A. ,  LARSEN, Glenn ,  DONALDSON, Debra, D. ,  LOWE, Leslie, D. ,  DUNUSSI, Kyri ,  MA, Margery ,  WITEK, JoAnn, S. ,  KASAIAN, Marion, T. ,  UNGAR, Michelle ,  CARRENO, Beatriz

IPC分类号： A61K39/395 ,  A61P19/02

CPC分类号： A61K31/519 ,  A61K31/42 ,  A61K31/453 ,  A61K38/1793 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2086 ,  A61K45/06 ,  C07K2319/30 ,  A61K2300/00

公开(公告)号：EP3254687A1

公开(公告)日：2017-12-13

申请号：EP17170098.2

申请日：2002-10-04

申请人： Genetics Institute LLC

发明人： CARTER, Laura ,  WHITTERS, Matthew J. ,  COLLINS, Mary ,  YOUNG, Deborah, A ,  LARSEN, Glenn ,  DONALDSON, Debra D. ,  LOWE, Leslie, D. ,  DUNUSSI, Kyri ,  MA, Margery ,  WITEK, JoAnn, S. ,  KASAIAN, Marion, T. ,  UNGAR, Michelle ,  CARRENO, Beatriz

IPC分类号： A61K38/00 ,  A61K39/39 ,  A61P19/02 ,  A61P35/00 ,  A61P31/00

CPC分类号： A61K31/519 ,  A61K31/42 ,  A61K31/453 ,  A61K38/1793 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2086 ,  A61K45/06 ,  C07K2319/30 ,  A61K2300/00

摘要： Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ("IL-21 R" or "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce imune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megkaryocytes, including transplant rejection and autoimmune disorders). IL-21 /IL-21 R agonists can be used by themnselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cvancer and infectious disorders.

摘要翻译： 使用IL-21或IL-21受体（“IL-21R”或“MU-1”）的激动剂或拮抗剂调节白细胞介素-21（IL-21）/ IL-21受体（MU- ）被披露。 例如，用于治疗或预防免疫细胞相关病变（例如，与一种或多种成熟T细胞（成熟CD8 +，成熟CD4 +，成熟CD8 + T细胞），成熟NK细胞，B细胞，巨噬细胞和巨核细胞，包括移植排斥和自身免疫性疾病）。 IL-21 / IL-21R激动剂可以自身使用或与抗原组合使用，例如作为佐剂（例如疫苗佐剂）以上调体内免疫应答，例如用于 用于治疗cvancer和感染性疾病。